Additional Study Information: This study is for individuals with advanced cancers. Only patients with non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), colorectal cancer (CRC), bladder cancer, ovarian cancer, esophageal cancer, gastric cancer, or renal cell carcinoma will be enrolled. The purpose of the study is to determine the best doses of study drugs MEDI0680 and MEDI4736 and determine how safe and tolerable MEDI0680 and MEDI4736 are when given together in subjects with advanced cancers. This study will also evaluate how much these study drugs are in your blood at various times, whether your immune system become activated following treatment or whether your body produces antibodies against the study drugs, as well as the effect both study drugs have on your cancer.